Biocon Sees Recovery In Biosimilars, Scope To Address Affordability In US

Mylan Partnership Bears Fruit

Biocon’s biosimilars business sees bounce-back in first quarter of fiscal 2021, with the US business witnessing gradually improving demand. The Indian company also sees potential for improved affordability in the US.

Shutter_M/Shutterstock.com
Biocon Biologics Regains Momentum In First Quarter • Source: Shutterstock

Biocon, Ltd.’s biosimilars business appears to have regained some momentum in the first quarter of fiscal 2021, after a tough previous quarter impacted by COVID-19-related challenges. The Indian firm is confident of a continued uptick in the US, where it sees headroom for greater affordability for biosimilars.

Revenues in the biosimilars segment rose by 19% to INR6.92bn ($92.6m) in the three-month period ended 30 June, led by...

More from Business

More from Scrip